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На сьогодні в Україні зареєстровано 8 комбінованих лікарських засоби кропиви собачої, настойку випус-
кають 10 вітчизняних підприємств, фасовану сировину – 3 вітчизняні заводи. Настойка собачої кропиви 
має певні недоліки: непостійність хімічного складу, і відповідно, фармакодинаміки; містить етиловий 
спирт, тому протипоказана дітям, вагітним, особам, діяльність яких потребує підвищеної уваги тощо. 
У зв’язку з цим, розробка стандартизованих лікарських засобів на основі настойки трави собачої кропи-
ви, яка б не містила в своєму складі етанол, є актуальним завданням. 
Мета. Визначити параметри стандартизації модифікованого сухого екстракту з настойки собачої 
кропиви та розробити проект методик контролю якості на цю субстанцію. 
Методи дослідження. Об’єктом дослідження був сухий екстракт на основі собачої кропиви настойки 
(Виробник: ОАО «Лубнифарм», серія 062021), який був модифікований з лізином. Для аналізу використо-
вували три серії екстрактів. 
При визначенні параметрів стандартизації одержаного сухого екстракту собачої кропиви трави вико-
ристовували стандартні фармакопейні методики. За основу розробки методик контролю якості на су-
хий екстракт собачої кропиви були взяті монографії ДФУ «Собачої кропиви трава», «Собачої кропиви 
настойка» та «Лізину гідрохлорид». 
Результати дослідження. Визначено параметри стандартизації модифікованого сухого екстракту со-
бачої кропиви трави. Запропоновано контролювати якість одержаного екстракту за такими показни-
ками: описом, розчинністю, ідентифікувати екстракт методом ТШХ за вмістом флавоноїдів, іридоїдів 
та лізину, втратою в масі при висушуванні, залишковою кількістю органічних розчинників (етанолу), мі-
кробіологічною чистотою, вмістом важких металів, кількісну стандартизацію проводити за вмістом 
флавоноїдів (не менше 2 %) та іридоїдів (не менше 0,5 %).  
Проаналізовано три серії екстракту згідно запропонованого проекту МКЯ, які повністю відповідали 
йому за всіма показниками.  
Висновки. Визначено параметри стандартизації модифікованого сухого екстракту з настойки собачої 
кропиви, який був одержаний з використанням лізину, та розроблено проект методик контролю якості 
на цю субстанцію. Проаналізовано три серії екстракту згідно запропонованого проекту МКЯ, які повні-
стю відповідали йому за всіма показниками. 
Ключові слова: собача кропива, трава, настойка, модифікація, лізин, сухий екстракт, біологічно актив-
ні речовини, параметри, стандартизація. 
 
1. Introduction 
Modern life in conditions of chronic stress and 
emotional overload leads to the appearance of symptoms 
of neurogenic and psychosomatic diseases. According to 
the results of modern studies, from 60 to 90 % of visits to 
the doctor are associated with stressful conditions. When 
choosing sedatives, more than 80 % of the population 
prefer pharma drugs. This is due to a number of reasons, 
including a comprehensive action aimed at various as-
pects of disease development, a high safety and effec-
tiveness profile, as well as relative cheapness and acces-
sibility [1, 2]. 
Herb of Leonurus cardiaca – one of the most used 
medicinal herbs with sedative action. The most common-
ly used medicinal product on the basis of this medicinal 
plant is the tincture of Leonurus cardiaca. Demand also 
includes combination drugs and functional supplements, 
which include biologically active substances (BAS) of 
Leonurus cardiaca. To date, in Ukraine there are 8 com-
bination of herbal medicines with Leonurus cardiaca,  
10 domestic enterprises produce tincture, 3 domestic 
enterprises pack Leonurus cardiaca [1, 3–5]. 
The main biologically active substances (BAS) of 
the Leonurus cardiaca are derivatives of flavone (apig-
enin) [6, 7], flavonol (quercetin, campferol), quinque-
loside, quercetin-7-glucoside, hyperoside, rutin, 
genququinine, quercitin, 5,4'-dihydroxy -7-methoxy 
flavone, kosmosian, 4-rutinoside of carboxylic acid [8, 
9]. Detected tannins (about 2–5 %), triterpene saponins 
(ursolic acid), steroid glycosides [10, 11], traces of essen-
tial oils (about 0.03 %): cariofilin, α-humumulin, α-
pinene, β-pinene, limonene, linalool; resin present, iri-
doid such as aucubin (ayugol, azhogoside, galyridoside) 
and diterpenes (leocardin and marubin) [12, 13]. 
 
2. Formulation of the problem in a general 
way, the relevance of the theme and its connection 
with important scientific and practical issues 
It should be noted that the tincture of Leonurus 
cardiaca has certain disadvantages: the incidence of 
chemical composition, and, accordingly, pharmacody-
namics; contains ethyl alcohol, therefore it is contraindi-
cated for children, pregnant women, persons whose ac-
tivities require increased attention, etc. Ethanol is not a 




pharmacologically indifferent substance, there is a dan-
gerous possibility of potentiation of certain drugs by 
ethanol [1, 14, 15]. 
In this regard, the development of standardized 
drugs based on the tincture of herb of Leonurus cardiaca, 
which would not contain ethanol in its composition, is an 
urgent task. 
 
3. Analysis of recent studies and publications in 
which a solution of the problem and which draws on 
the author 
Previously, in the works [16, 17], the technology 
of obtaining dry tincture of Leonurus cardiaca grass was 
substantiated, the essence of technology, which consists 
in replacing the alcohol with a dry excipient (sucrose, 
mannitol, sorbitol, etc.). The obtained product is charac-
terized by advantageous technological parameters: satis-
factory bulk properties, less hygroscopicity and stability 
during storage. 
Amino acids in extracts can form salts and com-
plexes with other BAS groups, for example, with phenol-
ic compounds, which alter their physico-chemical prop-
erties, affect solubility and bioavailability, total pharma-
cological effect. Modification of galenic drugs by various 
amino acids leads to an increase in their activity and the 
emergence of new pharmacological effects [18, 19]. 
Therefore, the modification of tincture of Leonurus car-
diaca with the help of amino acids and standardization of 
new dry extracts is an actual task of modern pharmacy 
[20, 21]. 
 
4. Allocation of unsolved parts of the general 
problem, which is dedicated to the article 
Having analyzed the current state of the research 
of medicinal products based on tincture of Leonurus 
cardiaca, it is advisable to determine the parameters of 
standardization of the previously obtained modified dried 
extract from this raw material, which showed the most 
pronounced sedative activity [22, 23].  
 
5. Formulation of goals (tasks) of Article 
Determine the standardization parameters of the 
modified dry extract from Leonurus cardiaca tincture in 
accordance with the requirements of the SPHU and de-
velop a draft quality control methodology for this sub-
stance. 
 
6. Statement of the basic material of the study 
(methods and objects) with the justification of the 
results 
The object of the study was dry extract based on 
the Leonurus cardiaca tincture (Manufacturer:  
OAO "Lubnifarm", series 062021), modified with lysine. 
For analysis, three series of extracts were used. 
In determining the parameters of standardization 
of the obtained dry extract of Leonurus cardiaca herbs 
used standard pharmacopoeial techniques. The basis of 
the development of quality control methods for dry ex-
tract of dog nettles was taken monographs SPHU 
"Leonurus cardiaca grass", "Leonurus cardiaca tincture" 
and "Lysine hydrochloride" [23–25]. 
The extract must be obtained from raw material 
that meets the requirements described in the monographs 
"Leonurus cardiaca grass" or "Leonurus cardiaca tinc-
ture" depending on the original product. 
Description. The Leonurus cardiaca extract dry 
makes a dry mass of lightweight brown light, bitter to 
taste with a faint odor. 
Solubility. To determine further technological 
manipulations with the extract and the direction of its 
use, it was necessary to determine its solubility. The 
extract is readily soluble in 50 % ethyl alcohol, moder-
ately soluble in 96 % ethyl alcohol and water, dissolves 
very little in chloroform and ether. Tests were conducted 
in accordance with the requirements of the SPHU 1.4. 
Identification. Since the standardization of the 
primary raw material (tincture, Leonurus cardiaca herb) 
controls the content of flavonoids, it is advisable to 
control the content of these substances in the resulting 
dry extract (method A) [23, 25]. Studies on the rela-
tionship between the chemical composition of extracts 
from Leonurus cardiaca herbs and their pharmacologi-
cal activity have shown that significant contribution to 
the sedative effect of these agents is iridoid, which is 
very labile substances, therefore they should also be 
determined in dry extracts (method B) [26, 27]. Since 
the modification of Leonurus cardiaca tincture is car-
ried out using lysine, it is also advisable to determine 
its presence (method C) [24].  
Identification of the major BAS groups in the ex-
tracts was carried out using thin-layer chromatography 
(2.2.27). 
Method A. Identification of the main substances of 
flavonoid nature [13, 23]. 
Test solution. 1 g of dry extract was dissolved in 
10 ml of 96 % ethanol or methanol, filtered through a 
paper filter, evaporated off the solvent and dissolved in 1 
ml of methanol. 
Comparison solution. 5 mg of hyperoside P and  
5 mg of routine P are dissolved in 5 ml of methanol R. 
Plate: TLC plate with a layer of silica gel R 
Moving phase: acetic acid P – water P- ethyl ace-
tate P (20:20:60). 
Volume of the sample to be applied: 30 μl, with 
stripes. Distance that must pass a moving phase: 10 cm 
from the start line. 
Drying: in the air.  
Detection: sprayed with a solution of dimethyla-
minobenzaldehyde P2, using 5 ml per plate in an area of 
200 mm
2; is heated at a temperature from 100 °С to  
105 °С for 10 minutes prior to the occurrence of stains; 
viewed in daylight. 
Results: The sequence of zones on the chromato-
grams of the test solution and the solution of the compar-
ison is given. On the chromatogram of the test solution, 
other zones can also be detected (Fig. 1). 
 




Fig. 1. Diagram of chromatogram of dry extract of Leonurus cardiaca herb 
 
 
Method B. Identification of basic substances of 
iridoid nature [28, 29]. 
About 5 g of dry extract (precise weight) are 
placed in a 100 ml round bottom flask, 50 ml of 40 % 
ethyl alcohol are heated and heated to a boiling water 
bath with reflux for 45 minutes. The extract is cooled 
and filtered through a cotton swab into a 100 ml volu-
metric flask. The solution is brought to the mark with  
40 % ethyl alcohol (Solution A). 
10 ml of the resulting solution is evaporated to  
5 ml. Transfer quantitatively the resulting solution to a 
10 ml volumetric flask, bring the volume of solution to 
the mark with water, and filter through a glass column 
of 1 cm in diameter with 3 g of aluminum oxide of the 
second degree of activity. 
On a chromatographic plate, 0.05 ml of the re-
sulting solution is applied. Chromatograph by ascending 
method in the solvent system chloroform P – methanol  
P – water P (80: 2: 0.1). After separation, the plate is 
removed and dried in air until the solvent is removed. 
Develop the plate with Stahl reagent (1.0 g of p-
dimethylaminobenzaldehyde dissolved in a mixture of 
50 ml of acetic acid, 5 ml of phosphorus acid and  
100 ml of water). The solution is suitable for 7 days.  
At least 3 zones of violet-purple color with Rf of 
about 0.40±0.05 (harpagoside), a spot with Rf of about 
0.6±0.05 (ayugoside), a spot with Rf of about 0.8 should 
appear on the chromatogram±0.05 (harpagoside acetate). 
Method C. Identification of lysine (2.2.27) [24]. 
Test solution. 1 g of dry extract was dissolved in 
10 ml of 96 % ethanol or methanol, filtered through a 
paper filter, evaporated off the solvent and dissolved in  
1 ml of methanol. 
Comparison solution. 10 mg of RS lysine hydro-
chloride is dissolved in water R and the volume of the 
solution is adjusted to 50 ml with the same solvent. 
Plate: TLC plate with a layer of silica gel R. 
Moving phase: ammonia concentrated P-2-
propanol P (30:70). 
On the starting line of the chromatographic plate, 
5 μl of the test solution and 5 μl of the comparison solu-
tion are applied. The plate is dried in air and placed in a 
chamber with a mixture of solvents. When the solvent 
front is 15 cm from the start line, the plate is removed 
from the chamber, dried at a temperature of 100 °C to 
105 °C until ammonia odor disappears and sprayed with 
a solution of ninhydrin R. The plate is heated at a tem-
perature of 100 °C to 105 °C for 15 min. The chromato- 
 
gram of the test solution reveals the main intensive zone 
at the level of the spot on the chromatogram of the com-
parison solution. 
Test. 
Loss in mass during drying. Not more than  
10.0 %. The definitions are carried out according to 
SPHU 2.0 (2.8.17). 0.50 g of ground powdered extract of 
the powder is placed in a batch and dried in a drying 
cabinet at a temperature of 100 °C to 105 °C for 3 hours. 
Cool in a desiccator and weigh. 
Residual amounts of organic solvents (ethyl al-
cohol). 
The content of alcohol in the extract of Leonurus 
cardiaca should not exceed 1.0 %. 
Approximately 1 g (exact weighting) of the ex-
tract is introduced into a 10 ml volumetric flask, dis-
solved in 7 ml of water, add 1 ml of acetone and 1,2-
dichloroethane (internal standards), bring the volume of 
solution to the mark with water, and mix. 
1 μl of the resulting solution and solution of the 
reference sample (RS) of ethyl alcohol are chromato-
graphed on a gas chromatograph with a flame-ionization 
detector, yielding not less than 5 chromatograms. 
The results of the analysis are considered reliable 
if the requirements of the test "Checking the suitability of 
the chromatographic system" are met. 
Heavy metals. For the purpose of toxicological 
safety in all types of phytochemical products it is neces-
sary to control the content of heavy metals, according to 
the requirements of the SPHU (2.4.8) their content 
should not be more than 100 ppm. 
Microbiological purity. For phytochemical agents 
microbial contamination is characteristic, therefore, it is 
necessary to control the amount of viable bacteria and 
fungi in the extract. Tests are carried out in accordance 
with the requirements of the SPHU, 2.6.12, 2.6.13 
To determine the total number of viable aero-
bic bacteria, 10 g of the extract is placed in a sterile 
measuring vessel, adjusted to 500 ml with a sterile 
neutralizing liquid containing 10 % polysorbate-80 
and 20 % isopropyl myristate. For 1 ml of the pre-
pared sample, they are sown using a two-layered 
method on each of five Petri dishes with a dense nu-
trient medium No. 1. 
To determine the total number of viable mush-
rooms, 10 g of the drug is placed in a sterile measuring 
vessel, brought to a 500 ml sterile neutralizing liquid 




containing 10 % polysorbate-80 and 20 % isopropyl  
 
myristate. 1 ml of the prepared sample was sown in a 
two-layered method on each of five Petri dishes with a 
dense medium No. 2. 
To test for the presence of enterobacteria and 
some other gram-negative bacteria, Pseudomonas aeru-
ginosa and Staphylococcus aureus, 10 g of the drug is 
placed in a sterile measuring vessel, adjusted to 500 ml 
sterile neutralizing liquid containing 10 % polysorbate-
80 and 20 % isopropyl myristate. For 50 ml of the pre-
pared sample, add 500 ml of nutrient medium No. 3 and 
No. 8. 
The standardization of the microbiological purity 
of the extract is established in accordance with the re-
quirements of the SPHU, 5.1.4, category 2. 
The preparation allows the total number of viable 
aerobic microorganisms: no more than 100 microorgan-
isms (bacteria and fungi in total) in 1 g. 
The presence of enterobacteria and some other 
gram-negative bacteria in 1 g is not allowed. The pres-
ence of Pseudomonas aeruginosa in 1 g is not allowed. 
The presence of Staphylococcus aureus in 1 g is not 
allowed. 
Composition of neutralizing liquid containing  
10 % polysorbate-80 and 20 % isopropyl myristate: poly-
sorbate 80–100 g, isopropyl myristate -200 g, lecithin 
(egg) – 3 g, histidine hydrochloride – 1 g, peptone enzy-
matic – 1 g, sodium chloride – 4.3 g, potassium dihydro-
gen phosphate – 3.6 g, disodium hydrophosphate dihy-
drate – 7.2 g, purified water – 1000 ml. 
Quantitative determination. The content of flavo-
noids in the extract of Leonurus cardiaca was determined 
by the spectrophotometric method in terms of the hyper-
oside for SPHU 2.2.25. The content must be at least 2 % 
in terms of hyperoside and dry substance. 
Initial solution. 1.0 g (exact weight) of dry ex-
tract is placed in a flask of 50 ml capacity, dissolved 
in 70 % ethyl alcohol, filtered through a paper filter, 
and the filtrate is evaporated in a water bath to an 
almost dry residue. To the resulting residue, add 0.5 
ml of a solution of 5 g / L of hexamethylenetetramine 
P, 15 ml of acetone P, 1 ml of hydrochloric acid P1, 
and add the flask to the reflux condenser and boil for 
30 min. After cooling, the contents of the flask are 
filtered through a paper filter in a volumetric flask of 
50 ml capacity, a 100 ml flask is washed with 15 ml of 
acetone P, the washing liquid is filtered through the 
same filter in the same measuring flask, the volume of 
the solution is adjusted with acetone P to 50.0 ml, 
rinsing flask and paper filter, and mix.  
20.0 ml of the resulting solution are placed in a 
separating funnel, 20 ml of water R is added and the 
mixture is shaken with 15 ml of ethyl acetate P, and then 
with 3 portions, each of 10 ml each, of ethyl acetate R. 
The ethyl acetate extracts obtained are combined in a 
divider funnel, washed in 2 portions , each 50 ml each, 
water R, filter over 10 g sodium anhydrous sulfate P into 
a volumetric flask and bring the volume of solution with 
ethyl acetate P to 50.0 ml. 
Test solution. To 10.0 ml of the stock solution, 
add 1 ml of the aluminum chloride R reagent and adjust 
the volume of the solution with 5 % (v / v) acetic acid P 
acid in methanol P to 25.0 ml.  
Compensation solution. 10.0 ml of the stock solu-
tion is adjusted with a solution of 5 % (v / v) of acetic-
acidic P acid in methanol P to a volume of 25.0 ml. 
Measure the optical density (2.2.25) of the test 
solution after 30 minutes in relation to the compensation 
solution at 425 nm wavelength. 
The content of the amount of flavonoids, in terms 









where A is the optical density of the test solution at a 
wavelength of 425 nm, m – weight of weight loss of dry 
extract of Leonurus cardiaca, in g. 
They use a specific index of absorption of hyper-
oside equal to 500. 
The content of iridoids in the extract of Leonurus 
cardiaca was determined by the spectrophotometric 
method in terms of harpagoside acetate. The content 
should be not less than 0.5 % in terms of garnet acetate 
and air-dry substance [29, 30]. 
10 ml of the resulting solution A (from the identi-
fication stage of the iridoid compounds) are evaporated 
to 5 ml. Transfer the resulting solution quantitatively into 
a volumetric flask of 10 ml capacity and bring the vol-
ume of solution to the mark with water. Filter through a 
glass column 1 cm in diameter with 3 g of aluminum 
oxide of the II degree of activity. 
Into a volumetric flask of 25 ml, place 5 ml of elu-
ate, add 5 ml of alkaline solution of hydroxylamine and 
stand for 5 minutes. Then add 10 ml of 1 M hydrochloric 
acid solution, add 1 % iron chloride solution (III) in a 0.1 
M solution of hydrochloric acid to the label and mix. 
The optical density of the resulting solution is 
measured on a spectrophotometer at a wavelength of 
512 nm. As a comparison solution, use a mixture made 
in a 25 ml volumetric flask: add 10 ml of a 1 M solution 
of hydrochloric acid to 5 ml of a hydroxylamine solution 
and bring to the mark with 1 % iron chloride solution 
(III) in a 0.1 M solution of hydrochloric acid. 
The content of iridoids in the extract in terms of 
harpagoside acetate (X) was calculated by the formula: 
 











where A – optical density of the investigated solution; 
56 – specific indicator of absorption of standard 
garpagide acetate immediately; m is the weight of the 
extract, g; w is the moisture content of the extract, %. 
The results of analysis of samples of herbs ex-
tracts according to the developed quality control method-








Results of analysis of Leonurus cardiaca herb dry extract according to the MQC project 
Quality indicators Permissible limits 
Results of determination in extracts, 
series 
1 2 3 
Description 
Amorphous hygroscopic powder from light 
brown to brown, bitter to taste with a faint odor. 
+ + + 
Solubility 
– 96 % ethanol moderately soluble + + + 
– 50 % ethanol easily soluble + + + 
– ether very little soluble + + + 
– chloroform very little soluble + + + 




Method А (TLC). According to MQC project 
+ + + 
Identification of iri-
doids 
Method В (TLC). According to MQC project 
+ + + 
Identification of lysine Method С (TLC). According to MQC project + + + 
Tests 
Loss in mass during 
drying 
Not more than 10 % 
 
6.9± 0.2 5.1± 0.3 4.5± 0.1 
Residual amounts of 
organic solvents: – 
ethanol 
Not more than 1,0 % 
0.4 0.3 0.2 
Heavy metals Not more than 100 ppm + + + 
Microbiological purity 
In 1 g of the drug no more than 100 microorgan-
isms (bacteria and fungi in total). The presence 
of enterobacteria and some other gram-negative 
bacteria in 1 g is not allowed. Presence of Pseu-
domonas aeruginosa in 1 g is not allowed. Pres-
ence of Staphylococcus aureus in 1 g is not al-
lowed. 
+ + + 
Quantitative determination 
The content of flavo-
noids 
not less than 2 %, in terms of hyperoside 
2.11±0.02 2.34±0.05 2.22±0.03 
The content of iri-
doids 
not less than 0,5 % in terms of harpagoside ace-
tate 
0.67±0.04 0.59±0.02 0.81±0.01 
Note. «+» – extract meets the requirements of the MQC 
 
 
According to the analysis, it can be concluded that 
all series of Leonurus cardiaca herbs extract dry meet the 
requirements of the developed MQC project. 
 
7. Conclusions from the conducted research 
and prospects for further development of this field 
The parameters of standardization of modified 
dried extract of tincture of Leonurus cardiaca, which was 
obtained using lysine, were determined, and a draft quali-
ty control methodology was developed for this substance. 
Three series of extract were analyzed in accordance with 
the proposed MQC project, which fully met all the indi-
cators. 
The resulting standardized extract will be used to 
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Мета. Метою статті є дослідження складу аптечки медичної, якою повинні бути укомплектовані по-
тяги. 
Матеріали та методи. У дослідженні застосовувалися такі методи, як контент-аналіз, аналітичний, порів-
няльний та логічний, експертних опитувань. У процесі дослідження застосовувалося експертне анкетування, в 
якому брали участь начальники потягів та проводники, загальною кількістю 453 особи. В опитуванні задіяні 
фахівці регіональних філій Укрзалізниці, а саме Львівської, Південно-Західної, Південної, Одеської, Прид-
непровської залізниць. Висновки респондентів є обгрунованими та збіжними, що підтверджено коефіцієнтом 
конкордації та критерієм Пірсону з урахуванням числа свободи, які перевищують нормативні (табличні) зна-
чення. Контент-аналіз використовувався для дослідження нормативної бази стосовно укомплектування по-
тягів аптечками медичними. 
Результати. Проведене анкетне опитування визначило, що всі респонденти впевнені в необхідності на-
явності в потязі аптечки медичної, але значна частина респондентів не знають про її наявність та мі-
сце розташування в потязі. 75,70 % респондентів вважають, що в потязі повинні бути в наявності два 
види аптечок медичних – у начальника потягу та у провідника. Лише 53,70 % респондентів відомий склад 
аптечки медичної, при цьому їх значна частина вважають за необхідне удосконалення складу аптечки та 
регулярного проходження відповідних курсів надання першої домедичної допомоги та отримання сертифі-
катів.  
На підставі контент-аналіз визначено, що пасажирський вагон повинен бути оснащений однією медич-
ною аптечкою та однією додатковою аптечкою на потяг на випадок аварії. При укомплектуванні ап-
течок медичних рекомендовано орієнтуватися аптечки медичні автомобільні. 
Досліджено аптечки медичні, якими укомплектовані потяги Росії, Республіки Казахстан та Республіки 
Біларусь. 
Висновки. Досліджено склад аптечок медичних, якими укомплектовані потяги України, Росії, Республі-
ки Казахстан та Республіки Біларусь. Визначені переваги та недоліки цих аптечок та запропоновано 
напрямки удосконалення аптечок медичних, якими укомплектовані потяги Укралізниці 
Ключові слова: аптечка медична, поїзд, аварія, залізниця, начальник поїзда, пострадавште, лікарський 
засіб, виріб медичного призначення, провідник, долікарська допомога 
 
1. Introduction 
One of the problems that is worrying around the 
world is the continued increase in rail accidents, as their 
consequences are quite significant, both in terms of 
irreversible human and material losses and time losses. 
The largest accidents involving trains include the 
accident at a railway in Denmark, which killed eight people 
[1]. In the Netherlands, a bicycle with four children was lost 
to the train, and two adults were traumatized [2]. In Serbia, a 
train and a bus collided, leaving five people dead,  
30 injured, and more than 10 people in severe condition are 
in the hospital [3]. In Ukraine, the passenger train № 139 
Kyiv-Kamyanets-Podilsky collided with a maneuvering 
locomotive, resulting in the first train of the train descended 
from the rails, hospitalized four children and one adult [4]. 
 
2. Formulation of the problem in a general 
way, the relevance of the theme and its connection 
with important scientific and practical issues 
In Ukraine, the number of traffic accidents on the 
railways is gradually decreasing, but the number of 
injured as a result of these accidents increases. Thus, 
during 2018, there were 79 accidents on the railroad, in 
which 16 people died and 30 [5] injured. During the 
corresponding period in 2017 there were 86 accidents, 
the number of deaths was 20, injured – 22 [6] (Fig. 1). 
 
